Home > Urology > ASCO GU 2021 > Testicular Cancer > New therapeutic option for early metastatic seminoma

New therapeutic option for early metastatic seminoma

Principal Investigator
Prof. Siamak Daneshmand, University of Southern California, USA
ASCO GU 2021
Phase 2, SEMS
The phase 2 SEMS trial demonstrated encouraging outcomes from retroperitoneal lymph node dissection (RPLND) for early metastatic (i.e. stage 2) testicular seminoma. The 2-year recurrence-free survival (RFS) rate was 87% and the overall survival rate (OS) was 100% among patients who underwent the procedure. The National Comprehensive Cancer Network Guidelines for management of stage 2A testicular seminoma remain unchanged for several decades, recommending chemotherapy and radiation therapy. Although these interventions are associated with excellent cure rates, they are also associated with long-term morbidity as well as secondary complications such as cardiac events, secondary cancers, metabolic syndrome, and lung disease. For this reason, investigators of the SEMS trial wished to explore other therapeutic options for young men with this cancer [1]. A seminoma will typically first spread to the retroperitoneal space. RPLND is commonly employed in tes...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on